Skip to main content
    S

    Sellas Life Sciences Group Inc (SLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.15
    +11.68 (+156.36%)

    Market Cap: $1.52B

    Last updated: Nov 17, 2026 at 4:44 PM ET

    Sellas Life Sciences Group Inc (SLS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sellas Life Sciences Group (SLS) has a market cap of $1.52B and an enterprise value of $1.39B. Its share count is up 86.76% from a year earlier.

    Total Valuation

    Enterprise value is 8.85% below the market cap, as cash exceeds debt.

    Market Cap$1.52B
    Enterprise Value$1.39B
    Latest price (Nov 17, 2026)$19.15

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 7.01% in the quarter ended Sep 30, 2026 and grew 72.22% a year over 2 years.

    Shares Outstanding202.44M
    Shares Change (YoY)+86.76%
    Shares Change (QoQ)+7.01%
    Share Count Growth (2Y CAGR)+72.22%

    Valuation Ratios

    P/B Ratio29.4x
    P/TBV Ratio29.8x

    Price Statistics

    The stock is up 1239.16% over 52 weeks and trades 73.93% above its 50-day average.

    Beta (1Y)1.76
    52-Week Change+1239.16%
    1-Month Change+82.55%
    3-Month Change+38.27%
    6-Month Change+152.31%
    5-Year Change+11.39%
    Total Return (1Y)+1239.16%
    Total Return (5Y CAGR)+22.77%
    Return vs SPY (1Y)+1092.84%
    Max Drawdown (1Y)-51.68%
    Max Drawdown (3Y)-58.52%
    Sharpe Ratio (1Y)1.75
    Correlation with SPY (1Y)0.17
    50-Day Average$11.01
    200-Day Average$8.88
    52-Week Range$1.39 to $15.88
    RSI (14 Days)76.6
    Average Volume (20 Days)13.04M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 14.92x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio14.92x
    Quick Ratio14.92x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -27.13% and return on assets is -25.35% over the last 12 months.

    Return on Equity (ROE)-27.13%
    Return on Assets (ROA)-25.35%
    ROIC (5Y Average)-31.52%

    Scores

    SLS has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$39.45M
    Pretax Income-$35.76M
    Net Income-$35.76M
    Reported EPS (TTM)-$0.20

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 93.42% of the $141.09M in total assets.

    Cash and Equivalents$134.71M
    Total Debt$0
    Net Cash$134.71M
    Net Cash Per Share$0.67
    Working Capital$129.29M
    Shareholder Equity$131.81M
    Book Value Per Share$0.65
    Tangible Book Value$129.89M
    Tangible Book Per Share$0.64
    Total Assets$141.09M
    Total Liabilities$9.29M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$27.30M
    FCF Per Share-$0.14
    Depreciation and Amortization$613.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    SLS does not pay a dividend.

    Buyback Yield-0.75%
    Shareholder Yield-0.75%

    Stock Splits

    The last split was a 1-for-50 reverse split on Nov 8, 2019.

    Last Split DateNov 8, 2019
    Split TypeReverse split
    Split Ratio1:50

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SLS

    What is SLS's market cap?

    Sellas Life Sciences Group has a market cap of $1.52B. Its enterprise value, which adds debt and subtracts cash, is $1.39B.

    How many shares of SLS are outstanding?

    Sellas Life Sciences Group has 202.44M shares outstanding. The count is up 86.76% from a year earlier.

    Does SLS pay a dividend?

    No. Sellas Life Sciences Group does not pay a dividend.

    How much debt does SLS have?

    Sellas Life Sciences Group has $0 of total debt and $134.71M of cash and equivalents, a net cash position of $134.71M.